Nobody asks what a platform is worth in 2031. Everybody asks what it's worth today

Nobody asks what a platform is worth in 2031. Everybody asks what it’s worth today.

That’s the whole story of how India covered its 2021 IPO cohort, and it’s why the coverage was wrong in a way that’s still costing readers money five years later.

Here’s what actually happened. A wave of new-age companies listed in 2021. Some had blockbuster debuts. A large number never saw their issue price again. And the commentary that followed treated both outcomes as verdicts on the business model itself, delivered in real time, using the valuation grammar built for FMCG and banks.

Nobody sat down and asked the only question that mattered: can this platform actually build durable revenue streams and convert them into shareholder returns over a decade, not a quarter.

The OFS objection is the laziest version of this. “It’s an offer for sale, the fund is just selling” gets repeated as if it settles the debate. It settles nothing. Private equity funds operate on borrowed time. Capital comes with an expiry date attached, and a fund that doesn’t return cash to its LPs doesn’t get to raise the next one. That forces funds to sell on a calendar, not on conviction. You will watch a PE investor exit below their own entry price, not because they’ve lost faith in the business, but because the fund’s life cycle has run out and someone back home needs a DPI number to show. Reading that exit as a verdict on the company is reading the wrong signal entirely.

None of this means traditional valuation doesn’t apply. It always applies. Discounted cash flows don’t stop working because a company calls itself a platform. What changes is the input you’re discounting. For a mature FMCG franchise, next year’s cash flow is a reasonable proxy for the steady state. For a platform business still building out unit economics across cohorts, geographies, and categories, next year’s cash flow tells you almost nothing about what the business is becoming. The right question was never “what is this worth now.” It was always “what can this platform be in three, five, seven years, and what has to be true to get there.”

Markets already know this, even when commentators don’t. Price is a daily referendum on exactly that forward question, re-run every session, discounting and re-discounting the probability of the seven-year outcome. The price is telling you something, constantly. This piece isn’t about what it’s saying right now. It’s about building the framework so you can read it for yourself, instead of borrowing someone else’s lazy verdict from 2021.

That framework is the hard part, and it’s the part almost nobody in Indian financial media actually teaches. Not “is the multiple high or low,” but: what does LTV/CAC actually look like once you strip out the marketing subsidy. What does cohort-level contribution margin tell you that blended P&L margin hides. When does a platform’s growth stop being financing-dependent and start being self-funding. How do you underwrite a terminal state for a business model that didn’t exist a decade ago.

Get that framework right, and the 2021 cohort stops being a cautionary tale and starts being a stock-picker’s dataset, full of names the market is still mispricing in both directions.

Next Sunday, I’m running a 2-hour deep dive on exactly this: roughly 15 listed new-age and platform names, and the actual lens to value them through, from LTV/CAC to projecting free cash flow for a business model built to look unprofitable for longer than a bank’s patience allows.

The 2021 verdict was rushed. The 2031 outcome hasn’t been written yet. That’s the gap this framework is built to close.

If you want the full teardown of all 15 names and the valuation lens, live, that’s what Sunday is for.

15 companies. One framework. Two hours. 30th August.

We will cover 15 new age companies in the upcoming webinar. There is an early bird price which you can avail, see you in the webinar.

No recommendation to buy, sell or hold anything. Views are personal. Just the framework, applied in public, so you can run it yourself on the next earnings call.

Get Early Bird Access

Growth Titans of Q1 - 13th September, 2026

Disclaimer: Neither Saket Mehrotra nor Beta to Alpha is a SEBI registered investment advisor. Views are my own and do not represent my previous or current employer. Any mention of stocks and securities is not a recommendation to buy / sell. The author may hold positions in the stocks mentioned and sell it without prior notice. Please do your own due diligence before investing. The purpose of this newsletter is for educational purposes only.